Copyright
©2010 Baishideng.
World J Gastroenterol. Jul 7, 2010; 16(25): 3133-3143
Published online Jul 7, 2010. doi: 10.3748/wjg.v16.i25.3133
Published online Jul 7, 2010. doi: 10.3748/wjg.v16.i25.3133
Table 4 Efficacy in the KRAS population
| Parameter | KRAS population | FOLFOX6 plus cetuximab (arm A) | FOLFIRI plus cetuximab (arm B) | |||
| KRAS wild-type (n = 62) | KRAS mutation (n = 55) | KRAS wild-type (n = 34) | KRAS mutation (n = 23) | KRAS wild-type (n = 28) | KRAS mutation (n = 32) | |
| PFS | ||||||
| Events, n (%) | 46 (74) | 47 (85) | 26 (76) | 20 (87) | 20 (71) | 27 (84) |
| Median1, mo (95% CI) | 8.9 (7.3-11.1) | 7.8 (6.4-8.4) | 9.1 (8.3-11.1) | 7.2 (5.5-9.7) | 8.4 (3.2-11.3) | 8.1 (7.3-8.5) |
| Logrank P-value | 0.0051 | 0.0196 | 0.1737 | |||
| HR2 (95% CI) | 0.55 (0.36-0.84) | 0.49 (0.27-0.91) | 0.66 (0.36-1.21) | |||
| PFS rate1, % (95% CI) | ||||||
| 3 mo | 81 (70-91) | 88 (80-97) | 90 (80-100) | 91 (79-100) | 69 (51-87) | 87 (75-99) |
| 6 mo | 70 (58-82) | 70 (57-83) | 77 (62-92) | 62 (41-83) | 61 (42-80) | 76 (60-91) |
| 9 mo | 49 (35-62) | 26 (14-39) | 53 (35-71) | 31 (11-52) | 43 (24-63) | 23 (7-39) |
| 12 mo | 29 (17-41) | 11 (2-20) | 28 (12-45) | 10 (0-24) | 30 (12-49) | 11 (0-24) |
| Overall survival | ||||||
| Events, n (%) | 37 (60) | 45 (82) | 21 (62) | 20 (87) | 16 (57) | 25 (78) |
| Median1, mo (95% CI) | 20.8 (16.6-26.9) | 15.9 (14.4-18.9) | 22.5 (17.1-28.9) | 15.2 (11.1-17.3) | 19.9 (11.9-na) | 18.9 (14.5-23.9) |
| Logrank P-value | 0.0296 | 0.0201 | 0.3608 | |||
| HR2 (95% CI) | 0.62 (0.40-0.96) | 0.48 (0.26-0.90) | 0.74 (0.39-1.40) | |||
| Survival rate1 (95% CI) | ||||||
| 9 mo | 79 (69-89) | 87 (78-96) | 85 (73-97) | 83 (67-98) | 71 (54-88) | 90 (80-100) |
| 12 mo | 72 (61-83) | 74 (63-86) | 76 (62-91) | 65 (46-85) | 67 (49-85) | 81 (67-95) |
| 18 mo | 55 (42-68) | 41 (28-55) | 55 (38-72) | 24 (6-42) | 56 (37-74) | 54 (36-72) |
| 24 mo | 44 (31-57) | 24 (12-36) | 43 (25-61) | 14 (0-29) | 45 (26-65) | 32 (14-49) |
| Best overall response, n (%) | ||||||
| CR | 6 (10) | 1 (2) | 2 (6) | - | 4 (14) | 1 (3) |
| PR | 27 (44) | 19 (35) | 17 (50) | 7 (30) | 10 (36) | 12 (38) |
| SD | 14 (23) | 26 (47) | 9 (26) | 12 (52) | 5 (18) | 14 (44) |
| PD | 8 (13) | 6 (11) | 3 (9) | 3 (13) | 5 (18) | 3 (9) |
| NE | 7 (11) | 3 (5) | 3 (9) | 1 (4) | 4 (14) | 2 (6) |
| ORR, n (%) | 33 (53) | 20 (36) | 19 (56) | 7 (30) | 14 (50) | 13 (41) |
| 95% CI | 40-66 | 24-50 | 38-73 | 13-53 | 31-69 | 24-59 |
| Odds ratio (95% CI) | 1.99 (0.95-4.18) | 2.90 (0.95-8.84) | 1.46 (0.53-4.07) | |||
- Citation: Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16(25): 3133-3143
- URL: https://www.wjgnet.com/1007-9327/full/v16/i25/3133.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i25.3133